BioSpace News Archive

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center study that confirmed the effectiveness of the GI Genius™ intelligent endoscopy module, which uses AI as an aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC).

Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, is adding two new innovations to its kinematically advanced and proven ATTUNE™ Knee portfolio: the ATTUNE™ Cementless Fixed Bearing Knee with AFFIXIUM™ 3DP Technology and the ATTUNE™ Medial Stabilized Knee System.

The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed business combination with Blade Therapeutics, Inc.

Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.

Alltrna, a Flagship Pioneering company unlocking transfer RNA biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, announced the formation of Alltrna’s Scientific Advisory Board with leading experts in RNA biology and therapeutics.

PolarityTE, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock.

Tend (“the company”), a microbiome solutions company, today announced the initiation of clinical studies for its Gut Microbiome Collect and Prep (CAP) device to prepare capsules for Fecal Microbiota Transplant (FMT) for patients with recurrent Clostridium difficile (C. diff) infections.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company’s President & CEO, David P. Luci, has been invited to present at the 2022 Virtual Growth Conference.

Leading wound care management and clinical services provider, WoundGenex, announced a strategic partnership with MiMedx Group, Inc., a transformational placental biologics company, to launch an exclusive version of WoundGenex’s Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.